• Explore /
  • Poster
  • / Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Abstract Poster

Authors

Richard Adams

Richard A. Adams

School of Medicine, Cardiff University, Cardiff, United Kingdom

Richard A. Adams , David Fisher , Susan Farragher , Alastair Scott , Christopher G Smith , Michelle D James , Jeremy Cheadle , Laura L Nichols , Angela M. Meade , Richard S. Kaplan , Richard H. Wilson , Harpreet S Wasan , Tim Maughan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3516)

DOI

10.1200/jco.2012.30.15_suppl.3516

Abstract #

3516

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: Richard Adams

First Author: Sebastian Stintzing

First Author: Christopher Williams

First Author: Chihiro Kosugi